



Our mission is to deliver a cure without compromise for patients through high precision cell therapies.

About Orca Bio

Orca Bio is a clinical-stage cell therapy company engineering high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases. Today, we are focused on redefining the traditional allogeneic stem cell transplant process by developing next-generation cell therapies with the goal of providing significantly better outcomes with dramatically fewer risks.

Since our founding, Orca Bio's leadership team has delivered on its mission, swiftly advancing our pipeline of investigational therapies from their foundational science into the clinic.

Redefining Transplant with Next-Generation Precision Cell Therapies

For over 50 years, allogeneic transplant has been many terminally ill patients' best hope to cure serious blood cancers such as acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndrome. This promise of a cure, however, comes with a compromise of treatment-related toxicities like chronic graft versus host disease (GvHD) that the patient may suffer from for the rest of their lives.

Orca Bio's lead investigational therapy, Orca-T, is designed to improve blood cancer patients' outcomes while lowering their risks of developing chronic GvHD and other serious transplant-related side effects. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) and is currently being evaluated in a pivotal, randomized Phase 3 clinical trial.

Orca Bio's Unique Approach

Orca Bio's platform uses a precision cell selection process that categorizes the more than 100 billion cells that patients would receive in a standard allogeneic transplant down to the less than one percent that actually provide therapeutic benefits. Using these cells, Orca Bio creates a high-precision proprietary mixture of immune and stem cells to build a designer immune system for patients. This designer immune system uses regulatory T cells to construct an immuno-regulatory environment to control serious complications, like GvHD, while enabling a potent anti-cancer effect.

Orca Bio has built its own manufacturing platform so it can reliably deliver its high-precision cell therapies at scale. Importantly, we have consistently achieved donor to patient vein-to-vein turnaround times of less than 72 hours across our ongoing clinical trials.

And this is only the beginning. We are advancing our next-generation programs to expand our pipeline to bring cell therapy to all patients who could benefit, including potential application in autoimmune disease and genetic disorders.

FAST FACTS

Year Founded
2016

Locations
Menlo Park, CA
(Headquarters)
Sacramento, CA
(Manufacturing Facility)

Number of Employees
100+

Number of Patients
Treated in Clinical Trials
300+

Privately Funded
More than \$300M in
Series A-D

Therapies Developed with the Input of Leading Treatment Centers

Working with leading institutions and top transplant centers, we have taken a rigorous approach to the design and implementation of our clinical trial programs.

- City of Hope
- Oregon Health & Sciences University
- Winship Cancer Institute of Emory University
- Stanford Health Care
- University of Texas MD Anderson Cancer Center
- Ohio State University
- UC Davis
- Sarah Cannon Research Institute
- Ronald Reagan UCLA Medical Center